drugset / Trial / NCT06429345
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
RandomizedParallel-groupQuadruple-blindPrevention
Summary
In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.
Timeline
- Start
- 2024-06-15
- Primary completion
- 2024-10-01
- Completion
- 2024-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coenzyme Q10 | Other / unclassified | 400 mg | Oral |
Indications
No indication recorded.